GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (STU:NOTA) » Definitions » Cyclically Adjusted PB Ratio

Novartis AG (STU:NOTA) Cyclically Adjusted PB Ratio : 3.29 (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Novartis AG Cyclically Adjusted PB Ratio?

As of today (2024-05-24), Novartis AG's current share price is €93.40. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €28.40. Novartis AG's Cyclically Adjusted PB Ratio for today is 3.29.

The historical rank and industry rank for Novartis AG's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:NOTA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.23   Med: 2.77   Max: 3.5
Current: 3.34

During the past years, Novartis AG's highest Cyclically Adjusted PB Ratio was 3.50. The lowest was 2.23. And the median was 2.77.

STU:NOTA's Cyclically Adjusted PB Ratio is ranked worse than
70.66% of 685 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs STU:NOTA: 3.34

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis AG's adjusted book value per share data for the three months ended in Mar. 2024 was €17.889. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €28.40 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted PB Ratio Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.14 2.94 2.79 2.81 3.04

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.79 3.00 3.16 3.04 3.13

Competitive Comparison of Novartis AG's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.



Novartis AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novartis AG's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=93.40/28.4
=3.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=17.889/107.3549*107.3549
=17.889

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201406 21.354 101.517 22.582
201409 22.885 101.247 24.266
201412 23.927 100.704 25.507
201503 29.158 100.339 31.197
201506 29.057 100.464 31.050
201509 28.528 99.785 30.692
201512 29.794 99.386 32.183
201603 27.081 99.475 29.226
201606 27.081 100.088 29.047
201609 28.125 99.604 30.314
201612 29.882 99.380 32.280
201703 26.713 100.040 28.666
201706 26.560 100.285 28.432
201709 26.179 100.254 28.033
201712 27.043 100.213 28.970
201803 24.738 100.836 26.337
201806 28.320 101.435 29.973
201809 28.915 101.246 30.660
201812 29.899 100.906 31.810
201903 17.994 101.571 19.019
201906 19.859 102.044 20.893
201909 21.060 101.396 22.298
201912 22.043 101.063 23.415
202003 20.128 101.048 21.384
202006 20.876 100.743 22.246
202009 20.337 100.585 21.706
202012 20.615 100.241 22.078
202103 18.903 100.800 20.132
202106 20.054 101.352 21.242
202109 21.571 101.533 22.808
202112 26.790 101.776 28.259
202203 25.255 103.205 26.271
202206 27.271 104.783 27.940
202209 28.558 104.835 29.244
202212 26.429 104.666 27.108
202303 23.187 106.245 23.429
202306 23.138 106.576 23.307
202309 17.397 106.570 17.525
202312 20.936 106.461 21.112
202403 17.889 107.355 17.889

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (STU:NOTA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novartis AG Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (STU:NOTA) Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (STU:NOTA) Headlines

No Headlines